

# CITATION REPORT

List of articles citing

The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease

DOI: 10.1186/s12882-019-1228-y  
BMC Nephrology, 2019, 20, 31.

**Source:** <https://exaly.com/paper-pdf/72901963/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
21	Real-World Associations Between Renin-Angiotensin-Aldosterone System Inhibition Therapy, Hyperkalemia, and Outcomes: A Clinical and Scientific Call to Action. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e014845	6	3
20	Tailoring treatment of hyperkalemia. <i>Nephrology Dialysis Transplantation</i> , <b>2019</b> , 34, iii62-iii68	4.3	3
19	[Austrian Consensus on High Blood Pressure 2019]. <i>Wiener Klinische Wochenschrift</i> , <b>2019</b> , 131, 489-590	2.3	3
18	Associations between serum potassium and adverse clinical outcomes: A systematic literature review. <i>International Journal of Clinical Practice</i> , <b>2020</b> , 74, e13421	2.9	19
17	Cost-analysis of persistent hyperkalaemia in non-dialysis chronic kidney disease patients under nephrology care in Italy. <i>International Journal of Clinical Practice</i> , <b>2020</b> , 74, e13475	2.9	2
16	Clinical and Economic Burden of Hyperkalemia: A Nationwide Hospital-Based Cohort Study in Japan. <i>Kidney Medicine</i> , <b>2020</b> , 2, 742-752.e1	2.8	3
15	Association between serum potassium levels and adverse outcomes in chronic kidney disease: the Fukushima CKD cohort study. <i>Clinical and Experimental Nephrology</i> , <b>2021</b> , 25, 410-417	2.5	1
14	Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction. <i>Journal of Human Hypertension</i> , <b>2021</b> , 35, 499-509	2.6	3
13	Should renin-angiotensin-aldosterone system inhibition enablement be a therapeutic target in CKD patients?. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> , 36, 1771-1772	4.3	
12	Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease. <i>Journal of Nephrology</i> , <b>2021</b> , 1	4.8	0
11	Challenging patient phenotypes in the management of anaemia of chronic kidney disease. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e14681	2.9	0
10	Binding Potassium to Improve Treatment With Renin-Angiotensin-Aldosterone System Inhibitors: Results From Multiple One-Stage Pairwise and Network Meta-Analyses of Clinical Trials. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 686729	4.9	0
9	Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study. <i>CKJ: Clinical Kidney Journal</i> , <b>2021</b> , 14, 1657-1664	4.5	1
8	Hyperkalemia Among Hospitalized Patients and Association Between Duration of Hyperkalemia and Outcomes. <i>Cureus</i> , <b>2020</b> , 12, e10401	1.2	
7	Pharmacoepidemiology in Cardiorenal Medicine. <b>2021</b> , 315-331		
6	A cost-effectiveness analysis of patiomer for the treatment of hyperkalemia in chronic kidney disease patients with and without heart failure in Spain.. <i>Journal of Medical Economics</i> , <b>2022</b> , 25, 640-649 <sup>2,4</sup>		
5	Pragmatic Diagnostic and Therapeutic Algorithms to Optimize New Potassium Binder use in Cardiorenal Disease. <i>Pharmacological Research</i> , <b>2022</b> , 106277	10.2	0

- 4 Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden. **2022**, 23, ○
- 3 Impacto económico del uso de patiomer en enfermedad renal crónica o insuficiencia cardíaca para el tratamiento de la hiperpotasemia crónica en España. **2022**, ○
- 2 A cost-effectiveness analysis of patiomer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure. **2023**, 24, ○
- 1 Cost Consequence Analysis of the Management of Hyperkalemia by Patiomer and Optimization of Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Chronic Kidney Disease Patients in Saudi Arabia. **2022**, 33, 39 ○